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To make human immunodeﬁciency virus type 1 (HIV-1)-based vectors safer for use in the research and
clinical setting, a signiﬁcant modiﬁcation to the HIV-1 genome has been the deletion of promoter and enhancer
elements from the U3 region of the long terminal repeat (LTR). Vectors containing this deletion are thought
to have no LTR-directed transcription and are called self-inactivating (SIN) lentivectors. Using four distinct
approaches, we show that SIN lentivectors continue to have promoter activity near the 5 LTR, which is
responsible for the production of full-length vector transcripts. To verify that transcripts derived from the LTR
in SIN lentivectors are competent for encapsidation and integration, we transduced a lentiviral packaging cell
line with a SIN lentivector and then observed the production of viable vector particles containing full-length
SIN lentivector genomes. We have also attempted to identify sequences in the SIN lentivector which are
responsible for transcriptional activation at the 5 LTR. Using different segments of the vector LTR and leader
region in a promoter assay, we have determined that the residual promoter activity is contained entirely within
the leader region and that, although this element is downstream of the transcription initiation site, it is capable
of initiating transcription from the 5 end of R in the LTR. Mutation of leader region binding sites for the
transcriptional activators downstream binding factor 1 (DBF1) and SP1 reduces transcription from the SIN
LTR by up to 80%. Knowledge of the potential for mobilization of HIV-1-derived SIN lentivectors will be
important for the design of future gene therapy trials with such vectors.
The inability of simple retroviral vectors based on the ge-
nome of the Moloney murine leukemia virus (MMLV) to
transduce nondividing cells has limited their usefulness for
both research and clinical purposes, which require efﬁcient
gene transfer into quiescent cells types such as hematopoietic
stem cells. The ability of lentiviral vectors to transduce such
nondividing cells (3, 13, 34, 51) separates them from MMLV-
based vectors, and this feature has fueled intensive develop-
ment of vector systems based on human immunodeﬁciency
virus type 1 (HIV-1) and other mammalian lentiviruses such as
HIV-2 (8), simian immunodeﬁciency virus (37, 45), feline im-
munodeﬁciency virus (7, 38), and equine infectious anemia
virus (36). A paramount concern in the development of these
systems has been to create transfer vectors which maintain the
ability to integrate into the genomes of nondividing cells but
which have been modiﬁed in ways that maximize their bio-
safety.
Three primary biosafety concerns involving vectors based on
the HIV-1 genome are (i) the risk of the vector packaging
system giving rise to replication-competent lentiviruses
through recombination between the transfer vector and pack-
aging constructs (53), (ii) the risk of insertional oncogenesis if
vectors with transcriptionally active long terminal repeats
(LTRs) are used, and (iii) the risk of mobilization of HIV-1-
based transfer vectors from transduced target cells by subse-
quent (or prior) infection with wild-type HIV-1 (1, 14). Per-
haps the most important modiﬁcation to HIV-1-based transfer
vectors which addresses all of these biosafety issues has been
the creation of self-inactivating (SIN) lentivectors by deleting
many of the core promoter and enhancer elements from the
U3 region of the vector (33). Due to the fact that the U3
deletion is copied to the 5 and 3 LTRs during reverse tran-
scription, integrated SIN vectors contain only LTRs with U3
deleted.
Transcriptional activation at the HIV-1 LTR has been
shown to depend on the presence of sequences both upstream
and downstream of the traditional transcription initiation site
at the U3-R junction (Fig. 1A). Directly upstream of the tran-
scription initiation site is a core promoter containing a classical
TATA sequence, ﬂanking E-boxes, and tandem binding sites
for SP1. In the region 5 of the core promoter, a large number
of binding sites for T-lymphoid- and myeloid-speciﬁc transcrip-
tion factors are present. Importantly, sequences overlapping
and downstream of the transcription initiation site are also
involved in activation of the HIV-1 promoter. An initiator
(Inr) element overlapping the U3-R junction (sequence 6t o
30 where the ﬁrst base of R is designated 1, a convention
which will be used throughout this report) has been found to
be required for transcription from the HIV-1 LTR (56). Ad-
ditionally, two NF-B sites in the R region are involved in
activating the LTR in response to mitogenic stimuli (32). Fur-
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8421ther downstream in the leader region (LR), three binding sites
for AP-1, as well as sites for NF-AT, DBF1, and SP1, have
been shown to be located in DNase-hypersensitive regions in
vivo, suggesting that some or all of these factors are bound to
this region in actively transcribed integrated HIV-1 proviruses
(10, 11). Elimination of these binding sites by deletion or
mutation has been shown to decrease transcription from the
HIV-1 LTR (11, 52). Additionally, a second Inr-like sequence
consisting of a CT triplet located at position 227 has been
found to be important for transcriptional competence of the
HIV-1 LTR (29).
The standard SIN deletion removed 400 of the 455 bases
comprising the U3 portion of the LTR. The deletion removes
the TATA sequence and SP1 sites at the core promoter as well
as many of the T-lymphoid- and myeloid-speciﬁc transcription
factor binding sites present upstream of the core promoter
(Fig. 1A). When integrated into the genome of target cells, this
SIN U3 proved to be severely disabled with respect to serving
as a promoter, and because no transcripts derived from the
LTR in SIN lentivectors were detected by Northern analysis
(60), the LTR in these vectors is commonly thought to be
completely transcriptionally inactive. We now demonstrate
that the transcriptional inactivation of the LTR of SIN vectors
is not complete and, moreover, that SIN lentivectors are ca-
pable of producing full-length genomic transcripts containing
the  sequence, making them competent for encapsidation
FIG. 1. Functional regions and binding sites present within the HIV-1 LTR and LR. (A) Schematic indicating locations of transcription factor
binding sites and functional regions of the LTR and LR. The scale indicates the conventional numbering of HIV-1 sequences where the ﬁrst base
of R is declared 1. The U3 region is not drawn to scale. Abbreviations: attL, left attachment site; DIS, dimerization initiation site; Inr, initiator;
ORF, open reading frame; pA, polyadenylation signal; PBS, primer binding site; SD, major splice donor; TAR, Tat response loop; , encapsidation
sequence. References 22, 24, 28, 42, and 52 were used to make this diagram. (B) Sequence of the LTR and LR from the sinLTR vector. ^, site
of SIN deletion. The transcription factor binding sites studied in this work are named, and their sequences are underlined. Numbers above the
sequence indicate positions in the vector sequence. (C) Sequence modiﬁcations used in this study. Here underlined nucleotides are those which
were altered in the mutants.
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tors are fully competent for a subsequent round of integration.
Using several different methods, we were able to conﬁrm the
transcriptional activity remaining near the SIN LTR (hence-
forth referred to as sinLTR for clarity). In an attempt to at-
tribute this transcriptional activity to speciﬁc cis-acting se-
quences in the LTR and LR of sinLTR vectors, we evaluated
portions of the LTR and LR for transcriptional activity in a
promoter screen. Additionally, we have analyzed transcription
patterns from vectors containing speciﬁc mutations at sites
previously identiﬁed to function as Inr and transcription factor
binding sequences. Through these analyses, we found no inde-
pendent transcription activating sequences in the sinLTR
U3-U5 region and determined that residual promoter activity
in SIN vectors is not dependent on the presence of the HIV-1
start site Inr nor the Inr-like sequence located at position 227
relative to the beginning of R. Rather, the elements responsi-
ble for promoting transcription from the sinLTR are located
downstream of U5 in the LR and are largely dependent on the
presence of DBF1 and SP1 binding sites in the 200 to 287
region.
MATERIALS AND METHODS
Cell culture. HEK 293 cells (henceforth designated 293 cells) and 293T cells
were grown in Dulbecco’s modiﬁed Eagle’s medium (DMEM) containing 10%
(vol/vol) fetal bovine serum (FBS), penicillin (100 U/ml), streptomycin (100
g/ml), and 2 mM L-glutamine. Jurkat T lymphoid cells, CEM T lymphoid cells,
K562 erythromyeloid cells, and HL60 metamyeloid cells were all obtained from
the American Type Culture Collection. Jurkat, CEM, and K562 cells were grown
in RPMI 1640 medium containing 10% FBS, penicillin (100 U/ml), streptomycin
(100 g/ml), amphotericin B (250 ng/ml), and 2 mM L-glutamine. HL60 cells
were grown in Iscove’s modiﬁcation of Dulbecco’s medium with 20% FBS,
penicillin (100 U/ml), streptomycin (100 g/ml), amphotericin B (250 ng/ml), and
0.01 mM 2-mercaptoethanol. The lentiviral packaging cell line, WAN-1 (T. Kafri,
unpublished data), was grown in DMEM with 10% tetracycline-free FBS, pen-
icillin (100 U/ml), streptomycin (100 g/ml), 2 mM L-glutamine, and 1 go f
doxycycline (Sigma Scientiﬁc, Inc., Brighton, Mass.)/ml until expression of HIV-1
packaging proteins and the vesicular stomatitis virus envelope glycoprotein
(VSV-G) were induced by culture in medium free of doxycycline.
Lentiviral vector construction. The HIV-1-derived vector plasmid pHR-
hCMV-eGFP (35), which contains wild-type LTRs and expresses the enhanced
green ﬂuorescent protein (eGFP), was the kind gift of Inder Verma (Salk Insti-
tute, San Diego, Calif.). The transfer vector expressed from pHR-hCMV-eGFP
is referred to as wtLTR-hCMV-eGFP in this report. The SIN HIV-1-derived
vector plasmid pCCL-hCMV-eGFP (9) was the kind gift of Luigi Naldini (Cell
Genesys, Foster City, Calif.). The transfer vector expressed from pCCL-hCMV-
eGFP is referred to as sinLTR-hCMV-eGFP in this report. wtLTR and sinLTR
vectors used in this work were derived from these two plasmids, respectively.
To create wtLTR and sinLTR vectors with a transgene directly 5 of the
internal promoter, the herpes simplex virus thymidine kinase (HSV-TK) gene
was cloned into a unique ClaI site upstream of the human cytomegalovirus
(hCMV) promoter in pHR-hCMV-eGFP and pCCL-hCMV-eGFP. The
HSV-TK gene was recovered from pG1NASVTK (31) by PCR with Pfu Turbo
polymerase (Stratagene, La Jolla, Calif.) by using oligonucleotide primers which
create ClaI sites at both ends of the gene: 5TKClaI (5-AGAATCGATTATGG
CTTCGTACCCCTG-3) and 3TKClaI (5-CCGAATCGATTCAGTTAGCCT
CCCCCC-3).
Lentiviral vectors with wtLTRs or sinLTRs containing no internal promoter
were produced by removing the hCMV promoter from pHR-hCMV-eGFP or
pCCL-hCMV-eGFP, respectively, by digestion with BamHI and ClaI, followed
by blunting with Pfu Turbo polymerase and ligation with T4 DNA ligase. These
vectors are referred to as wtLTR-eGFP and sinLTR-eGFP. Vectors with sinL-
TRs containing mutations in the LTR and LR but lacking internal promoters
were constructed in a similar fashion from the mutated vector constructs de-
scribed below.
sinLTR lentivectors with additional regions of U3 deleted were prepared by
PCR-mediated site-directed mutagenesis. The mutated sequences and their lo-
cations in the LTR and LR are depicted in Fig. 1B and C. All site-directed
mutagenesis reactions were performed by using polyacrylamide gel electrophore-
sis-puriﬁed oligonucleotides with Pfu Turbo polymerase according to directions
accompanying the QuikChange-XL kit (Stratagene) with the following thermo-
cycler conditions: 17 cycles of 95°C for 1 min, 58°C for 1 min, and 68°C for 2 min
per kb of plasmid length. The resulting PCR products were digested with DpnI
(Invitrogen, Carlsbad, Calif.) to destroy the input template plasmid, and 2 lo f
this mixture was used to transform competent DH5. The vector containing the
minimal 24-bp U3 sequence (the attL site) was generated by following the
method of Iwakuma et al. (23) with oligonucleotide primers 5CCLattL (5-GC
TAATTCACTCCCAGGGTCTCTCTGGTTAG-3) and 3CCLattL (5-CTAAC
CAGAGAGACCCTGGGAGTGAATTAGC-3), with pCCL-hCMV-eGFP as a
template. Final constructs were veriﬁed by sequencing. To further compromise
the sequence of the Inr at the transcription initiation site of the LTR in pCCL-
hCMV-eGFP, three bases were changed from GGG to TTT by following the
method of Rittner et al. (41) with oligonucleotides 5CCL1TTT (5-GTTTAG
TGAACCGTTTTCTCTCTGGTTAG-3) and 3CCL1TTT (5-CTAACCAG
AGAGAAAACGGTTCACTAAAC-3) (mutated bases are underlined).
Vectors containing mutated transcription factor binding sites in U5 and the
LR were generated by PCR-mediated site-directed mutagenesis by following the
method of Van Lint et al. (52). The SP1 mutant was generated with oligonucle-
otides 5SP1mut (5-GCGCGCACGGCAAGATTCGAGGTGCGTCGACTGG
TGAGTACG-3) and 3SP1mut (5-CGTACTCACCAGTCGACGCACCTCGA
ATCTTGCCGTGCGCGC-3). Because the DBF1 mutation involves changing
six A residues to G residues, we found that mutation primers making all six
mutations at once could not be used successfully, perhaps due to the excessive
length and C/G content of the primers. Consequently, the DBF1 mutant was
generated in two steps by using oligonucleotides 5aDBF1mut (5-GACTTGAA
AGCGCCCGGGAAACCAGAG-3) and 3aDBF1mut (5-CTCTGGTTTCCC
GGGCGCTTTCAAGTC-3) for the ﬁrst step, the product of which was used as
the template for a second round of mutagenesis with the oligonucleotides 5bDBF1mut
(5-GAACAGGGACTTGCCCGCGCCCGGGAAC-3) and 3bDBF1mut (5-GT
TTCCCGGGCGCGGGCAAGTCCCTGTTC-3). The AP-1/AP-3L mutant was
generated by using oligonucleotides 3AP3Lmut (5-CCCTCAGACCCTTGTA
GGCAGTGGTTTAAATCTCTAGCAGTG-3) and 3AP3Lmut (5-CACTGCT
AGAGATTTAAACCACTGCCTACAAGGGTCTGAGGG-3). The CTCTCTC
sequence at positions 227 to 233, which is suspected to have Inr activity (29),
was modiﬁed to GAGAGAG by using oligonucleotides 5CCL227GA3 (5-G
AAACCAGAGGAGGAGAGAGGACGCAGGAC-3) and 3CCL227GA3
(5-CTCCCTGCGTCCTCTCTCCTCCTCTGGTTTC-3). The successful muta-
tion of each of the above sites was veriﬁed by sequencing.
Vector supernatant preparation and titer determination. Vector supernatants
were prepared by calcium phosphate-mediated cotransfection (calcium phos-
phate transfection kit; Invitrogen) of 293T cells as previously described (48) by
using 10 g of transfer vector plasmid, 10 go fp R 8.9 packaging plasmid (59),
and 2 g of pMD.G(VSV-G) envelope plasmid (35). 293T cells were plated on
poly-L-lysine-coated 10-cm-diameter plates in DMEM with 10% FBS and al-
lowed to adhere for 6 h prior to transfection. Twelve hours after application of
the DNA precipitate, the cells were rinsed three times with Dulbecco’s phos-
phate-buffered saline (PBS) and then subjected to induction with 10 mM sodium
butyrate (Sigma) in DMEM with 10% FBS. After 12 h, the cells were rinsed once
with PBS and then refed with fresh medium. Vector supernatants were collected
24 or 48 h after application of fresh medium and then ﬁltered through a 0.2-
m-pore-size syringe ﬁlter and stored at 80°C. Pseudo-sinLTR supernatants
were produced in the same fashion; however, 10 g of pHIT60, a plasmid
expressing the MMLV packaging proteins Gag and Pol (48), was used in place of
pR8.9. To determine vector titers, 293 cells were plated at 2 	 10
5 cells per well
in six-well plates and allowed to adhere for 6 h, at which time the media were
removed and replaced with 1 ml of undiluted or diluted vector supernatant
supplemented with 8 g of Polybrene (Sigma)/ml. At the time of vector addition,
the number of cells per well was recorded for use in calculating the titer. The
vector supernatants remained on the cells overnight and were then replaced with
fresh medium. Seventy-two hours after the addition of vector supernatant, the
cells were harvested and assessed by ﬂow cytometry for eGFP expression. Titers
were calculated by using the following equation: [(% of eGFP-positive cells/100)
	 dilution factor 	 number of cells].
Assessment of vector mobilization. 293 and WAN-1 cells were plated at 10
5
cells per well on six-well plates in DMEM with 10% FBS and permitted to adhere
for 6 h prior to transduction. The medium was then aspirated and replaced with
1 ml of vector supernatant supplemented with 8 g of Polybrene/ml. Transduc-
tion was veriﬁed 1 week after the application of the vector supernatant by
assessment of eGFP expression from the vectors with a FACSCalibur ﬂow
cytometer and CellQuest software (Becton Dickinson, San Jose, Calif.). In vector
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Trypsin-EDTA every other day for 1 week to remove input vector particles prior
to assessment of cell media over these cells for the presence of mobilized vector
particles. After 1 week of passaging, the cells were replated at near conﬂuence on
poly-L-lysine-coated six-well plates in 1 ml of fresh medium. Once daily for ﬁve
consecutive days, the 1 ml of medium over these cells was removed and replaced
with fresh medium. The removed medium was ﬁltered through a 0.2-m-pore-
size syringe ﬁlter and placed onto 293 cells which had been freshly plated. All ﬁve
supernatant collections were supplemented with 8 g of Polybrene/ml and added
to the same batch of 293 cells. These cells were passaged in culture for 2 weeks
and then assessed by ﬂow cytometry for the presence of mobilized vector.
To verify that the eGFP-positive 293 cells which had been exposed to medium
conditioned by WAN-1 cells transduced with the sinLTR-hCMV-eGFP vector
had been transduced by full-length vector capable of genomic integration, cells
were passaged for an additional 2 weeks (total of 1 month in culture posttrans-
duction) and genomic DNA was then harvested from these cells with a DNeasy
kit (QIAGEN, Valencia, Calif.). Genomic DNA was then analyzed by ALU-
mediated PCR (4, 49) to verify the presence of integrated sinLTR vectors in the
target cells. The ﬁrst-round PCR was performed on 100 ng of genomic DNA with
the following primers, the ﬁrst of which anneals to the ALU sequence present at
random locations in the human genome while the second anneals to the 3 end
of the U5 region of the LTR: ALU(s), 5-TCCCAGCTACTGGGGAGGCTG
AGG-3; 3U5.1end, 5-CTGCTAGAGATTTTCCACACTGAC-3. The ﬁrst-
round PCR was performed on genomic DNA from mock-transduced 293 cells
and genomic DNA from 293 cells exposed to media conditioned by WAN-1 cells
transduced with the sinLTR-hCMV-eGFP vector (designated 293sin) by using
the following thermocycler conditions: 30 cycles of 95°C for 50 s, 60°C for 50 s,
and 72°C for 3 min. The second-round PCR was performed on 1/50th of the PCR
product from the ﬁrst round by using primers which amplify the region of the
LTR between the 5 end of U3 and the portion of U5 just 5 to the 3U5.1end
primer, 5U3 (5-CTAATTCACTCCCAACGAAGACAAG-3) and 3U5.2int
(5-CCACACTGACTAAAAGGGTCTGAG-3). The second-round PCR was
performed with the following thermocycler conditions: 30 cycles of 95°C for 50 s,
64°C for 50 s, and 72°C for 30 s. To control for the possibility that input genomic
DNA in the ﬁrst-round PCR was responsible for positive ampliﬁcation in the
second round, we included a control reaction in which the ﬁrst-round PCR was
performed without primers on 100 ng of 293sin genomic DNA. When 1/50th of
this reaction mixture was used in the second-round PCR, the absence of a PCR
product indicated that visible product in other lanes was ampliﬁed only from the
product of the ﬁrst-round PCR product.
Vector transductions. For studies of vector transcript production, lymphocytic
and myeloid cell lines were transduced as follows: 10
5 cells were plated in 100 l
of RPMI 1640 (no serum) in 48-well plates to which 100 l of undiluted or
diluted vector supernatant was added. Cells were incubated for 12 h, followed by
the addition of 200 l of media. Each day thereafter, the volume was doubled
with fresh media and cells were successively passaged up to six-well plates.
Transduced cells were cultured for a minimum of 1 week prior to any subsequent
analysis. When transduction of cells with equivalent numbers of vector particles
was desired, the titers of vector supernatants were determined by p24 immuno-
assay (Coulter Corp., Fullerton, Calif.).
TK production assay. Jurkat cells were transduced with the wtLTR-hCMV-
eGFP and sinLTR-hCMV-eGFP vectors with or without the HSV-TK gene
inserted upstream of the internal hCMV promoter. After passage in culture for
1 week or more, cells were assessed by ﬂow cytometry for eGFP expression. Pools
of cells containing each vector which were 10 to 30% eGFP positive were then
plated in duplicate for treatment or nontreatment with ganciclovir (GCV; Roche
Pharmaceuticals, Nutley, N.J.) in six-well plates at 5 	 10
5 cells per well. The
treated cells were passaged in media containing 20 g of GCV/ml for 2 weeks,
with medium and GCV replacement every 3 days. Nontreated cells were pas-
saged at the same frequency in medium lacking GCV. After 2 weeks, the treated
cells were replated in fresh medium lacking GCV and all cells were passaged for
an additional 2 weeks. All groups were then analyzed by ﬂow cytometry for eGFP
expression. In each group, dividing the percentage of cells remaining eGFP
positive with GCV treatment by the percentage of eGFP-positive cells without
GCV illustrates the GCV sensitivity of cells transduced with each vector.
Vector transcript detection by RT-PCR. RNA from stably transduced cells was
harvested by using RNAqueous (Ambion, Inc., Austin, Tex.). The RNA was then
treated with DNA-free (Ambion), with a slight modiﬁcation of the manufactur-
er’s directions in that the DNase I treatment was performed twice to completely
eliminate residual genomic DNA. Five hundred nanograms of total DNase
I-treated RNA served as the template for cDNA synthesis by using a reverse
transcriptase PCR (RT-PCR) kit (Clontech, Palo Alto, Calif.) with a reverse
transcription primer which anneals to the eGFP transgene present in each of the
vectors, GFP.RTp (5-CCGTCCTCCTTGAAGTCGATGCCC-3). For every
reaction, a control was set up which lacked the RT enzyme. Dilutions of cDNA
were used as templates in PCRs with primers which detect a 314-bp fragment of
eGFP 5 to the site at which the GFP.RTp primer anneals, 5GFP (5-ATGGT
GAGCAAGGGCGAGGAGCTG-3) and 3GFP (5-GCCGTCGTCCTTGAA
GAAGATGGTG-3). One to eight microliters of the cDNA was used as the
template for PCRs to identify the presence of the  region by using primers
which anneal to the R region and the 3 end of the LR, 5R (5-GAGCCTGG
GAGCTCTCTGGCTAAC-3) and 3u/sGag (5-CTCTCTCCTTCTAGCCTCC
GC-3). Similar dilutions were also used to detect the presence of the HSV-TK
gene in cDNA from cells transduced with HSV-TK containing vectors by using
oligonucleotides 5TK-ID (5-ACGATCTTGGTGGCGTGAAACTCC-3) and
3TK-ID (5-GTCATCGGCTCGGGTACGTAGACG-3). For semiquantitative
analysis of transcript expression, ethidium bromide-stained gels were visualized
with an Eagle Eye charge-coupled device and densitometry was performed with
EagleSight software (Stratagene).
Tat response assay. 293 cells were stably transduced with wtLTR-eGFP and
sinLTR-eGFP vectors lacking an internal promoter. These cells were plated onto
poly-L-lysine-coated six-well plates and transfected in duplicate with increasing
amounts of the plasmid pSV2-tat72 (16) acquired from the AIDS Research and
Reference Reagent Program, Division of AIDS, National Institute of Allergy
and Infectious Diseases, National Institutes of Health (NIH; Rockville, Md.).
Seventy-two hours after transfection, cells were harvested and the levels of eGFP
expression within each group were analyzed by ﬂow cytometry. At the same time,
RNA was harvested from the transfected cells and subjected to DNase I diges-
tion three times to remove input plasmid and expression from pSV2-tat72 was
veriﬁed by RT-PCR with oligonucleotides 5tat72 (5-ATGGAACCGGTCGAC
CCGCGTC-3) and 3tat72 (5-AGACAGAGAAACCTGGTGGGTC-3).
-Containing transcripts were also detected in this cDNA by using the previously
described  primers.
Promoter screening constructs. The promoterless pGL3-Basic plasmid con-
taining the ﬁreﬂy luciferase gene was acquired from Promega (Madison, Wis.).
Several fragments of the wtLTR and sinLTR regions, as well as portions of the
SIN lentivector LR, were cloned into the KpnI-to-NheI sites in pGL3-Basic by
using the listed primers (which contain the appropriate restriction enzyme sites,
as designated in their names) to recover the fragments from pHRhCMV-eGFP
or pCCL-hCMV-eGFP where appropriate. All PCRs were performed with Pfu
Turbo polymerase. The wtLTR and sinLTR regions (U3-U5) were recovered
from the appropriate plasmid by using oligonucleotides 5U3KpnI (5-AAAAG
GTACCACTGGAAGGGCTAATTC-3) and 3U5NheI (5-ATGAGCTAGCA
CTGCTAGAGATTTTCC-3). The LR (1 to 180) segment was recovered by
using oligonucleotides 5LR1KpnI (5-TGCTGGTACCGGGTCTCTCTGGTTA
G-3) and 3U5NheI (described above). The LR (181 to 335) segment was re-
covered by using 5LR181KpnI (5-ATCTGGTACCGTGGCGCCCGAACAG
G-3) and 3LR335NheI (5-TCGCGCTAGCCTCTCTCCTTCTAGCC-3). The
LR (200 to 287) segment was recovered by using 5LR200KpnI (5-GAACGGT
ACCTTGAAAGCGAAAGGG-3) and 3LR287NheI (5-GCATGCTAGCGTC
GCCGCCCCTCGC-3). Segments containing mutations in either the DBF1 or
SP1 site were recovered by using pCCL-hCMV-eGFP(DBF1/SP1) with those
two mutations as a template. The LR (200 to 287) DBF1/SP1 segment was
recovered by using 5LR200DBF1KpnI (5-GAACGGTACCTTGCCCGCG-
3) and 3LR287SP1NheI (5-GCATGCTAGCGTCGACGCACCTCG-3).
The LR (200 to 235) DBF segment was recovered by using 5LR200
DBF1KpnI (described above) and 3LR235NheI (5-GAGTGCTAGCTCGAG
AGAGCTCTGG-3). The LR (236 to 287) SP1 segment was recovered by
using 5LR236KpnI (5-CTCTGGTACCGCAGGACTCGGCTTGC-3) and
3LR287SP1NheI (described above). The LR (253 to 287) SP1 segment was
recovered by using 5LR253KpnI (5-CTCGGGTACCTGAAGCGCGCACGG
C-3) and 3LR287SP1NheI (described above). The LR (288 to 335) segment
was recovered by using 5LR288KpnI (5-GGGCGGTACCTGGTGAGTACGC
CAA-3) and 3LR335NheI (described above).
Luciferase assay. 293 cells were plated on poly-L-lysine-coated six-well plates
at 2 	 10
5 cells per well. After 6 h, the medium was aspirated and replaced with
fresh medium and the cells were then transfected in triplicate by calcium phos-
phate precipitation with 1,250 fmol of each of the pGL3 constructs into which
various fragments of the LTR or LR had been cloned. To control for differing
transfection levels, 14.7 fmol of the control plasmid pRL-CMV, which expresses
Renilla luciferase from the hCMV promoter, was cotransfected with each of the
pGL3 constructs. After 12 h of culture, the transfection mixture was aspirated
and replaced with fresh media. The cells were cultured until 72 h after the
initiation of transfection, at which time the cells were rinsed once with PBS and
then lysed with passive lysis buffer (Promega) for assessment of ﬁreﬂy and Renilla
luciferase expression by using the dual-luciferase assay kit (Promega) according
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sured with a Lumat 9501 luminometer (Berthold, Wildbad, Germany).
Assessment of mutated lentivector expression. Mutations were made to the
sinLTR-eGFP vector plasmid as described above. Equivalent amounts of each
vector, as determined by p24 immunoassay, were used to transduce Jurkat cells
in triplicate. Cells were carried in culture for 1 week as described above and then
analyzed for eGFP expression by ﬂow cytometry. To assess transduction efﬁ-
ciency with each vector, genomic DNA was isolated from transduced cells and
checked by PCR for the eGFP sequence by using the eGFP primers described
above. Simultaneous ampliﬁcation of glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) with primers included with the RT-PCR kit (Clontech) from
each sample allowed us to verify that equal amounts of genomic DNA were
added to each reaction mixture. PCR products were quantiﬁed on an ethidium
bromide agarose gel by densitometry. The percentage of cells expressing eGFP
from each vector was then divided by the GAPDH-corrected measurement of
eGFP transduction into cells.
Prediction of  stem-loop conformation. The prediction of the most thermo-
dynamically favorable conformation of the  loop was made with Mfold (61) by
using a tool available online (http://www.bioinfo.rpi.edu/applications/mfold/old
/rna/).
RESULTS
SIN lentivectors produce packageable full-length tran-
scripts. To determine whether SIN lentivectors produce full-
length genomic transcripts capable of mobilization by wild-type
HIV-1, we used the lentiviral packaging cell line WAN-1
(Kafri, unpublished) to represent an HIV-1-infected cell.
WAN-1 cells are a clone of 293 cells which have been engi-
neered to express the HIV-1 proteins Gag/Pol and Rev, each
from separate expression cassettes under the control of Tet-off
promoters (18). Additionally, this cell line expresses the
VSV-G envelope and eGFP from a bidirectional Tet-off pro-
moter. Expression of the HIV-1 packaging proteins, the
VSV-G envelope, and eGFP is largely repressed when doxy-
cycline is present in the media. Repression of these proteins is
required for the expansion of WAN-1 cells because VSV-G
and the protease component of Pol are cytotoxic when ex-
pressed constitutively (2, 15, 25, 26, 54). The coexpression of
VSV-G and eGFP from a single expression cassette permits
veriﬁcation that the cells have been fully derepressed when
cultured in doxycycline-free media by observation of eGFP
expression by ﬂuorescent microscopy or ﬂow cytometry. After
the WAN-1 cells had been successfully derepressed, they were
transduced in parallel with 293 cells, using lentivector super-
natants produced by transient transfection of 293T cells (Fig.
2A). Vectors used included the wtLTR-hCMV-eGFP vector
packaged with HIV-1 Gag/Pol and VSV-G, the sinLTR-
hCMV-eGFP vector packaged with HIV-1 Gag/Pol and
VSV-G, and a pseudo-sinLTR supernatant in which the sin-
LTR-hCMV-eGFP vector was packaged with MMLV Gag/Pol
and VSV-G. Although MMLV Gag is capable of encapsidating
unspliced HIV-1 vector genomes to a low degree (57), we have
never produced infectious vector particles with this combina-
tion (unpublished data); thus, the pseudo-sinLTR supernatant
serves as a control for the passive transfer of transfer vector
plasmid or preformed eGFP within the vector supernatant. To
reduce the amount of plasmid in the supernatant used to
transduce the WAN-1 and 293 cells, we diluted the superna-
tants 1:10 in fresh D10 and used two hits of this dilution
separated by 24 h to transduce the cells. Twelve hours after the
second addition of vector supernatant, the cells were washed
several times with PBS and refed with fresh media. During the
week after transduction, the cells were passaged every other
day with trypsin-EDTA to facilitate the removal of residual
input vector particles. After 1 week, the transduced WAN-1
and 293 cells were analyzed by ﬂow cytometry for eGFP ex-
pression (Fig. 2A). As expected, even nontransduced WAN-1
cells were largely eGFP positive due to the aforementioned
expression of eGFP in these cells when they are derepressed.
This made it difﬁcult to monitor the transduction of WAN-1
cells with eGFP-expressing vectors; however, the eGFP expres-
sion seen in 100% of the 293 cells which were transduced in
parallel with the WAN-1 cells by the wtLTR and sinLTR
vectors packaged with HIV-1 Gag/Pol demonstrate that these
supernatants had high titers (Fig. 2A). The lack of eGFP ex-
pression in 293 cells subjected to the pseudo-sinLTR superna-
tant veriﬁes that no viable vector particles were present in this
supernatant. It has been shown that lentivector supernatants
prepared by transient transfection contain a large amount of
residual transfer vector plasmid (44) which theoretically could
transfect the WAN-1 and 293 cells exposed to the supernatants
we used; however, we observed no spontaneous transfection of
cells exposed to the pseudo-sinLTR supernatant (Fig. 2A).
The transduced WAN-1 and 293 cells were plated at near
conﬂuence, and for ﬁve consecutive days, medium conditioned
by these cells was removed, ﬁltered though a 0.2 m-pore-size
syringe ﬁlter, and placed onto a fresh batch of 293 cells. These
293 cells were passaged in culture for 2 weeks and then ana-
lyzed for eGFP expression. As seen in Fig. 2A, 293 cells ex-
posed to media conditioned by mock-transduced WAN-1 cells
showed no evidence of transfer of the eGFP gene from the
WAN-1 cells. As expected, WAN-1 cells transduced with the
wtLTR vector mobilized this vector, such that 9.38% of the
target 293 cells were eGFP positive. The lack of eGFP expres-
sion in target 293 cells exposed to media conditioned by 293
cells transduced with the wtLTR vector demonstrates that
there were no residual input vector particles present on these
cells which could be carried to the ﬁnal target 293 cells. We
thus conclude that all eGFP-positive target 293 cells were
transduced by vector genomes mobilized from the WAN-1
cells. In this experiment, which is representative of three sim-
ilar experiments, we observed a relatively low amount of
wtLTR vector mobilization. We believe this is partially attrib-
utable to the fact that WAN-1 cells do not express Tat, which
is required for high-level expression from the wtLTR. Addi-
tionally, when WAN-1 cells are used to package high-titer
vector supernatants, it is usually advantageous to grow them in
the presence of the histone deacetylase inhibitor sodium bu-
tyrate (Kafri, unpublished). For these experiments, we did not
add sodium butyrate to the media because we were concerned
that this might artiﬁcially favor expression from the wtLTR
and sinLTR.
When target 293 cells were exposed to media conditioned by
WAN-1 cells which had been transduced by the sinLTR vector,
we observed a signiﬁcant level of eGFP positivity in the target
293 cells of 0.71%. Again, the absence of eGFP expression in
target 293 cells exposed to media conditioned by sinLTR vec-
tor-transduced 293 cells shows that transfer of input vector
particles is not responsible for the eGFP positivity of the target
cells. Thus, we conclude that we have demonstrated mobiliza-
tion of a sinLTR vector from a cell producing HIV-1 packaging
proteins. To control for the possibility that residual transfer
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WAN-1 cells and that expression from such spontaneously
transfected plasmids could account for the apparent mobiliza-
tion of the sinLTR vector from these cells, we also performed
a control transduction of WAN-1 cells with the pseudo-sinLTR
supernatant which did not contain HIV-1 vector particles. The
lack of transfer of eGFP positivity to target 293 cells exposed
to medium conditioned by these WAN-1 cells permits us to
exclude that explanation for our results. Further characteriza-
tion of our ability to mobilize sinLTR vectors from an HIV-1
packaging cell line is under way (Kafri, unpublished).
Mobilized SIN lentivectors integrate into target cell chro-
mosomal DNA. In Fig. 2B, we demonstrate, by ALU-mediated
PCR analysis, that the target 293 cells exposed to medium
conditioned by WAN-1 cells transduced by the sinLTR vector
contained integrated sinLTR vector. The ALU element is a
short interspersed nuclear element which is randomly located
throughout the human genome and accounts for roughly 11%
of its sequence (27). Although it has been demonstrated that
SIN lentivectors favor integration into actively transcribed re-
gions of the genome (46), a portion of these semirandomly
integrated vectors will be located within a few kilobases of an
ALU element. In the ﬁrst round of our ALU-mediated PCR
analysis, the sequence between ALU elements and the 5 LTR
of nearby integrated vectors was ampliﬁed. Then, a second-
round PCR was performed on 1/50th of the ﬁrst-round PCR
product, using primers which ampliﬁed the region between the
5 end of U3 and the 3 end of U5 upstream of the annealing
site for the U5 primer used in the ﬁrst-round PCR. When this
series of reactions was performed on mock-transduced 293
cells, the visible smear from the ﬁrst-round PCR represents
products primed solely by the ALU primer but no product was
present in the second-round PCR. In contrast, when per-
formed on the 293 cells into which the sinLTR vector had been
FIG. 2. Lentivector mobilization. (A) Lentivector supernatants prepared by transfection of 293T cells with the indicated vector plasmids (V,
transfer vector; P, packaging construct; E, envelope) were used to transduce WAN-1 and 293 cells in parallel. Upper cytometry plots indicate eGFP
expression on the x axis 1 week after transduction. Supernatants collected from the transduced WAN-1 and 293 cells were ﬁltered and placed onto
fresh 293 cells on ﬁve consecutive days. Lower plots represent eGFP expression in these 293 cells 2 weeks later. (B) ALU-mediated PCR was
performed with the indicated ﬁrst- and second-round primers. Both reactions were performed on mock-transduced 293 cells (293mock) and 293
cells exposed to media conditioned by WAN-1 cells transduced with the sinLTR-hCMV-eGFP vector (293sin). A control reaction with cDNA from
the latter was performed in which the ﬁrst-round primers were excluded (NoR1p).
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product, indicating that the vector was integrated into the
genome of these cells. Additionally, we note that the length of
this product is speciﬁc to the sinLTR vector. Since the second-
round primers anneal to the 5 and 3 ends of the LTR, the
product would be 400 bp longer if ampliﬁed from a wtLTR
vector. Consequently, we can conﬁrm our conclusion that this
experiment demonstrates mobilization of a sinLTR vector
rather than an artifact produced by accidental introduction of
the wtLTR vector at any stage of the experiment. To control
for the possibility that genomic DNA put into the ﬁrst-round
PCR was ampliﬁed by the second-round primers, we per-
formed a control in which the 293sin genomic DNA was sub-
jected to the ﬁrst-round PCR in the absence of primers and
then to the second-round PCR with primers. Because this
result was negative, we can conclude that the product seen in
the ALU-mediated PCR performed on 293sin cell genomic
DNA was ampliﬁed only from integrated vectors.
Transgenes upstream of the internal promoter in SIN len-
tivectors are expressed. To demonstrate that a transgene
placed downstream of the LTR in a sinLTR vector but up-
stream of the vector’s internal promoter could be expressed,
we constructed vectors containing the HSV-TK gene down-
stream of the LTR in both the wtLTR-hCMV-eGFP and
sinLTR-hCMV-eGFP vectors (Fig. 3A). These vectors were
packaged with HIV-1 Gag/Pol and VSV-G and then used to
transduce Jurkat T lymphoid cells.
Expression of transcripts from the LTR of both the wtLTR
and sinLTR vectors was detected by using RT-PCR on DNase
I-treated RNA isolated from the transduced Jurkat cells. As
seen in Fig. 3B, we were able to speciﬁcally detect the HSV-TK
sequence in RNA isolated from cells transduced with the
wtLTR and sinLTR vectors bearing this gene upstream of the
internal promoter. This assay was not performed quantita-
tively, and the brighter intensity of the HSV-TK product from
the RNA isolated from cells transduced with the sinLTR-TK-
hCMV-eGFP vector compared with RNA from cells trans-
duced with the wtLTR-TK-hCMV-eGFP vector is accounted
for by the fact that a larger percentage of cells were positive for
the sinLTR vector (21.9%) than the wtLTR vector (12.8%).
RT-PCR with primers detecting the eGFP transgene expressed
from the internal promoter of each vector was used as a con-
trol to verify cDNA synthesis.
To provide further evidence for expression of HSV-TK from
the LTR in both the wtLTR and sinLTR vectors, we deter-
mined the susceptibility of Jurkat cells transduced with wtLTR
and sinLTR vectors which did or did not contain the HSV-TK
gene upstream of the internal promoter to GCV-induced cell
death. Pools of Jurkat cells which were 10 to 30% positive for
each vector were plated in duplicate for exposure to media
which did or did not contain 20 g of GCV/ml. Cells were
passaged for 2 weeks under these conditions, and then all cells
were carried for an additional 2 weeks in media lacking GCV.
When cells treated with GCV had recovered to normal growth
patterns, they were analyzed for eGFP expression by ﬂow cy-
tometry. We calculated the ratio of eGFP positivity in popu-
lations which had been treated with GCV compared to those
which had not been so treated (Fig. 3C). Figure 3C represents
the average of data from ﬁve separate experiments. As ex-
pected, Jurkat cells transduced with wtLTR and sinLTR vec-
tors lacking the HSV-TK gene did not exhibit signiﬁcant
changes in the ratio of eGFP positivity with or without GCV.
Cells transduced with wtLTR-TK-hCMV-eGFP demonstrated
high-level sensitivity to GCV-induced cell death, and the ratio
of eGFP positivity with or without GCV treatment was 0.25 

0.2 (mean 
 standard deviation). The sensitivity of Jurkat cells
transduced with wtLTR-TK-hCMV-eGFP compared to cells
transduced with wtLTR-hCMV-eGFP was found by Student’s
FIG. 3. Expression of a transgene upstream of the internal promoter in the wtLTR and sinLTR vectors. (A) Diagram of vectors containing the
HSV-TK transgene upstream of the internal promoter and the primers used to identify TK and eGFP transcripts. (B) DNase I-treated RNA from
Jurkat cells which were not transduced (NT) or were stably transduced with wtLTR and sinLTR vectors that did or did not contain the HSV-TK
gene upstream of the internal hCMV promoter were analyzed by RT-PCR for TK and eGFP sequences.  and  indicate the addition or omission
of RT from cDNA synthesis. (C) Jurkat cells stably transduced with the indicated vectors were treated or not treated with 20 g of GCV/ml for
2 weeks and then cultured in GCV-free media for 2 weeks, at which time the ratio of eGFP-positive cells with or without GCV treatment was
determined by ﬂow cytometry (error bars indicate standard deviations).
VOL. 78, 2004 FULL-LENGTH GENOMIC TRANSCRIPTS FROM SIN LENTIVECTORS 8427t test to be highly signiﬁcant (P 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duced with sinLTR-TK-hCMV-eGFP exhibited a mild sensi-
tivity to GCV with an eGFP positivity with or without GCV
ratio of 0.76 
 0.08, and this sensitivity was signiﬁcant com-
pared to Jurkat cells transduced with sinLTR-hCMV-eGFP (P
 0.004).
SIN lentivectors lacking an internal promoter express de-
tectable transgene. Another method we used to demonstrate
expression from the LTR of sinLTR vectors was to construct
wtLTR and sinLTR vectors completely lacking internal pro-
moters. To accomplish this, the hCMV promoter was removed
from the wtLTR-hCMV-eGFP and sinLTR-hCMV-eGFP vec-
tors to create wtLTR-eGFP and sinLTR-eGFP (Fig. 4A).
These vectors were packaged with HIV-1 Gag/Pol and VSV-G
and used to transduce Jurkat T lymphoid cells and K562 eryth-
romyeloid cells. Due to the low-level expression from the
sinLTR, we did not expect to be able to get a reliable titer for
the sinLTR-eGFP vector by standard titer determining proto-
cols, wherein limiting dilution transduction of 293 cells is per-
formed, followed by analysis of eGFP expression by ﬂow cy-
tometry. Consequently, we determined the vector titers by p24
immunoassay. For unknown reasons, the titer of sinLTR-
eGFP (132.5 
 8.1 ng/ml) was signiﬁcantly lower than the titer
of wtLTR-eGFP (1401.7 
 25.1 ng/ml). Nevertheless, wtLTR-
eGFP was diluted with media to equal the p24 titer of sinLTR-
eGFP, and serial dilution transductions with these two vectors
were performed on Jurkat and K562 cells. Figure 4B demon-
strates the patterns of eGFP expression in these cells 1 week
after transduction with each vector at a concentration of 26.5
ng/ml. Signiﬁcant levels of eGFP expression were observed in
cells transduced with both vectors; however, the level of ex-
pression from sinLTR-eGFP was lower than that from wtLTR-
eGFP, as indicated by the lower mean ﬂuorescence intensities
(MFIs) in cells transduced with sinLTR-eGFP (Fig. 4B). These
data indicate that the 5 LTR in SIN lentivectors retains tran-
scriptional activity, but it is signiﬁcantly lower than the level of
transcription from the wtLTR. A similar comparison of expres-
sion from the wtLTR and sinLTR, in which differences in
transduction efﬁciency are accounted for, is described below
(see Fig. 8A).
Transcripts from the LTR in SIN vectors are detectable by
RT-PCR. We developed a semiquantitative RT-PCR assay
with which we could determine the relative activities of the
wtLTR and sinLTR in the context of vector constructs con-
taining internal promoters. DNase I-treated RNA from stably
transduced lymphoid (Jurkat and CEM) and myeloid (K562
and HL60) cells was used as a template for reverse transcrip-
tion by using a primer which anneals to the eGFP transgene
present in the vectors (Fig. 5A). This produced a pool of
strictly vector-derived cDNAs with a high likelihood that all
would be complete to the 5 end of the transcript. RT is prone
to early termination; thus, minimizing the distance the enzyme
must travel increases the likelihood it will reach the 5 end of
the RNA template. In this case, the 5 ends of LTR-derived
transcripts were within 2.6 kb of the RT primer. Transcripts
from the LTR were detected by using primers which anneal to
R (just downstream of the traditional transcriptional start site
at the U3-R junction) and the LR, producing a product 330 bp
in length (Fig. 5A). We refer to these as -containing tran-
scripts, and these can only be derived from the 5 LTR. We
also performed PCR with primers which detect a 314-bp frag-
ment of eGFP. Transcripts containing this sequence can be
derived from either the LTR or the internal promoter. Since
the  and eGFP reactions are of similar efﬁciency (Fig. 5B),
we semiquantitatively determined the percentage of transcripts
originating from the LTR by densitometrically measuring the
amount of  and eGFP transcripts and dividing the former by
the latter (Fig. 5B).
We found that in cells transduced with the wtLTR vector,
transcripts from the LTR represented 6 to 37% of the vector-
derived transcripts, with the highest percentage being seen in T
cells. In cells transduced with the sinLTR vector, the percent-
age of transcripts derived from the LTR ranged from 1 to
5.5%, again with the highest LTR transcriptional activity in T
cells. Comparison of these data allow us to conclude that the
sinLTR retains roughly 15% of the transcriptional activity
found in the wtLTR in the context of vectors containing inter-
nal hCMV promoters. We have conﬁrmed that -containing
transcripts can also be detected from sinLTR vectors contain-
ing other internal promoters (data not shown). Using this as-
say, transcripts originating from the LTR in a SIN lentivector
were also identiﬁed in freshly transduced mouse bone marrow
(data not shown), indicating that expression from the sinLTR
is not restricted to cell lines or to human cells.
Transcription from the LTR in SIN lentivectors is not en-
hanced in the presence of Tat. Having demonstrated by several
different approaches that SIN vectors produced transcripts
from the 5 LTR, we sought to characterize the mechanism by
which these full-length genomic transcripts are produced. As a
ﬁrst step toward identifying whether transcription from the
sinLTR involves an RNA polymerase II (RNAP II) holoen-
zyme with the same constituents as that found in the holoen-
zyme which nucleates on the wtLTR during transcription, we
tested the Tat-responsiveness of the sinLTR. To accomplish
FIG. 4. Expression from wtLTR and sinLTR vectors lacking inter-
nal promoters. (A) Diagram of vectors containing the wtLTR or sin-
LTR but lacking an internal promoter. (B) Percentage of eGFP-pos-
itive cells and MFI in Jurkat and K562 cells transduced with 26.5-ng/ml
wtLTR-eGFP and sinLTR-eGFP.
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eGFP and found that the sinLTR vector was capable of ex-
pressing in this cell type (data not shown). We then transfected
the 293 cells transduced with the two vectors with increasing
amounts of pSV2-tat72, a plasmid which expresses an active
but truncated version of HIV-1 Tat (16). Seventy-two hours
after transfections, the level of eGFP expression was deter-
mined by ﬂow cytometry (Fig. 6A). Increases in the MFI of
eGFP expression demonstrated transcriptional activation at
the LTR by Tat. We only saw such transactivation in cells
transduced with the wtLTR vector. No change in eGFP inten-
sity was detected in cells transduced with sinLTR-eGFP, even
at the highest levels of transfected Tat (Fig. 6A). To ensure
that Tat was expressed in all cells, RT-PCR detections of Tat
were performed on DNase I-treated RNA from all cells (Fig.
6B). Thus, we conclude that transcription from the wtLTR, but
not that from the sinLTR, is transactivated by Tat.
A portion of the LR is responsible for transcriptional acti-
vation from the sinLTR. To facilitate identiﬁcation of se-
quences in the sinLTR vector which are responsible for the
residual promoter activity in or near the LTR, we adopted a
promoter screening assay in which fragments of the LTR and
LR were cloned into a plasmid, pGL3-Basic, which has a ﬁreﬂy
luciferase (F-luc) gene situated downstream of the site into
which the fragments were cloned. Equimolar amounts of each
construct were cotransfected into 293 cells with pRL-CMV, a
plasmid which serves as a transfection control by expressing
Renilla luciferase (R-luc) from the hCMV promoter. Seventy-
two hours after transfection, relative expressions of F-luc and
R-luc were determined with a luminometer. The relative lucif-
FIG. 5. RT-PCR detection of transcripts from the LTR in wtLTR and sinLTR lentivectors. (A) Diagram indicating sites annealed to by the RT
primer and primers used to amplify regions from - and eGFP-containing transcripts. (B) The plasmid template titration for  and eGFP PCRs
indicates that these two reactions are of similar efﬁciency. (C)  and eGFP PCRs were performed on DNase I-treated RNA from cells stably
transduced with wtLTR-hCMV-eGFP or sinLTR-hCMV-eGFP vectors. For detection of -containing transcripts, 2 or 8 l of cDNA was used in
the PCR, whereas 0.1 or 1 l of cDNA was used in the eGFP PCR. RT and RT indicate the addition or omission of RT from cDNA synthesis.
Quantities of PCR products were determined by densitometry, and the percentage of vector transcripts originating from the LTR (%LTR) was
calculated by using the equation {[(density 	 input cDNA)]/[eGFP(density 	 input cDNA)] 	 100}.
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expression from pGL3-Basic, which was low, but not negligible
(Fig. 7A). When the wtLTR U3-U5 was assayed, it produced
high levels of F-luc, greater even than a control plasmid from
which F-luc was expressed by the simian virus 40 promoter
(Fig. 7A). However, when the sinLTR U3-U5 region was an-
alyzed, it gave no detectable expression while a construct con-
taining the 335-bp LR sequence between the 5 end of R and
the 3 end of the  region, designated LR (1 to 335), gave a
signiﬁcant level of expression (roughly 2% of the expression
level from the wtLTR). Using random hexamer-primed RT-
PCR followed by PCR with the  primers identiﬁed in Fig. 5,
we veriﬁed that the LR (1 to 335) construct was producing
transcripts originating from the 5 end of this sequence or
perhaps upstream of it (Fig. 7B). The level of expression seen
with the LR (1 to 335) construct was equaled by that from a
construct containing the region 181 to 335 (Fig. 7A), indi-
cating that no LTR sequences in R or U5 are required for the
level of transcription seen with the complete LR construct.
We then analyzed the effect of mutating transcription factor
binding sites in this region which have been identiﬁed by other
investigators to play a role in transcription from the HIV-1
LTR. Binding sites for DBF1 and SP1 are located within the
LR (181 to 335) fragment, and these factors have been found
in nuclease-sensitive sites in vivo, indicating that they may be
bound in integrated HIV-1 proviruses and thus may play a role
in transcription (10, 40, 52). Indeed, Van Lint et al. demon-
strated that mutation of these sites signiﬁcantly decreased tran-
scription from an intact wtLTR in HIV-1 (52). When we ana-
lyzed the LR (181 to 335) fragment with either the DBF1 or
the SP1 site mutated individually, the expression decreased
slightly; however, combining the DBF1 and SP1 mutations led
to a roughly 50% decrease in expression from the construct.
This led us to conclude that DBF1 and SP1 work cooperatively
to promote transcription at this site, but because expression
was not completely eliminated, we believe there are other
factors in this region continuing to promote transcription.
In an attempt to isolate these other sequences, we made
further mutations and truncations within the LR (181 to 335)
construct. Through these analyses, we localized the bulk of the
transcriptional promotion to the 87-bp fragment LR (200 to
287). Other than the DBF1 and SP1 sites, the only other
potential transcriptional activation site in this region which has
been previously studied is a CT triplet, designated (CT)
3,
which has been identiﬁed as having Inr-like activity within
HIV-1 proviruses (29). When this site was mutated to a GA
FIG. 6. Tat-responsiveness of wtLTR and sinLTR vectors. (A) 293 cells stably transduced with wtLTR-eGFP and sinLTR-eGFP vectors were
left untreated, mock transfected, or transfected with 2, 4, or 8 g of pSV2-tat72. Seventy-two hours after transfection, the MFI of each group was
determined by ﬂow cytometry. (B) RNA isolated from cells in each group at 72 h after transfection was analyzed by RT-PCR for expression of
Tat- and -containing transcripts. WT, wild type; UT, untreated; pos, positive; neg, negative; , present; , absent.
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(29); however, when we added this mutation to the LR (200 to
287) construct, we did not see a signiﬁcant change in the level
of transcription (Fig. 7A). Through the analysis of even shorter
segments, we conclude that DBF1 is the only relevant site in
the LR (200 to 235) segment, since the LR (200 to 235)
DBF1 construct did not express. Ultimately, we isolated a
34-bp fragment, which contained the SP1 site, and which ex-
pressed at a signiﬁcant level even if the SP1 site was mutated,
indicating that elimination of SP1 binding may be incomplete
FIG. 7. Screen for promoter activity in the sinLTR and LR. (A) Indicated regions of the sinLTR or LR were cloned into a ﬁreﬂy luciferase
expression plasmid, pGL3-Basic, which lacks a promoter. Equimolar amounts of each construct were cotransfected into 293 cells with a Renilla
luciferase expression plasmid, pRL-CMV, which expresses Renilla luciferase from the hCMV promoter. Relative luciferase expression was
determined 72 h after transfection, and results are expressed relative to the expression from pGL3-Basic. Bars represent the means of the results
from at least three separate transfections (
 standard deviations). (B) Cells transfected with pGL3-Basic and the construct containing the LR (1
to 335) were analyzed by RT-PCR for expression of the entire region with previously described  primers which amplify the region between the
beginning of R and the  portion of the LR. pos, positive; neg, negative; , present; , absent.
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located in this segment (Fig. 7A).
Analysis of U5 and LR mutated SIN lentivectors. We next
analyzed the effect of DBF1 and SP1 binding site mutations in
the context of a vector to determine whether the decrease in
expression seen in the promoter screen was predictive of what
would happen in the vector context. We constructed sinLTR
vectors with the appropriate mutations in the LTR or LR by
using PCR to mutagenize the speciﬁc sites (see Materials and
Methods and Fig. 1B and C for mutant sequences). To simplify
analysis of the effects of LR and LTR mutations on LTR-
derived transcription, we used the assay described for Fig. 4, in
which vectors lacking internal promoters were used to demon-
strate expression derived from the LTR. To accomplish this,
we mutated sites within the LTR and LR in the vector sinLTR-
eGFP, packaged the mutant vectors with HIV-1 Gag/Pol and
VSV-G, and then transduced Jurkat cells with equal amounts
of each vector as determined by p24 immunoassay. For both
cell types, transduction with each vector was performed in
triplicate. One week after transduction, cells were analyzed by
ﬂow cytometry to determine the percentage that were positive
for eGFP expression. To correct our interpretation of the
eGFP expression for possible differences in the transduction
efﬁciency using each vector, we harvested genomic DNA from
the transduced cells and the amount of transduced vector was
determined by PCR ampliﬁcation of the eGFP gene by using
the eGFP primers described previously (Fig. 3 and 5). To
control for the amount of genomic DNA put into the PCRs, we
simultaneously ampliﬁed a GAPDH product and then quanti-
tated the GFP and GAPDH products densitometrically (data
not shown). Figure 8A shows the relative expression levels
from each construct in Jurkat cells after correction for differ-
ences in transduction efﬁciency, all normalized to the expres-
sion level from the sinLTR-eGFP vector having no additional
mutations.
In accord with our ﬁnding from the promoter assay that
DBF1 and SP1 are primarily responsible for transcription from
the sinLTR, the sinLTR-eGFP vector bearing mutations in the
DBF1 and SP1 binding sites, designated sinLTR(DS), exhib-
ited a 79% decrease in expression compared to the sinLTR-
eGFP vector without additional mutations. Because mutation
of the DBF1 and SP1 sites did not completely eliminate ex-
pression in the promoter assay constructs (Fig. 7A), we believe
that either SP1 binding to the mutant site is not completely
eliminated or that there are additional sequences near the SP1
site involved in transcriptional activation, and that this may be
wholly or partially responsible for expression from the sinLTR
(DS) vector.
In an attempt to further decrease the expression from this
mutant, we mutated additional sites which have been impli-
cated in transcriptional activation in HIV-1. First, we mutated
an AP-1/AP-3-like (henceforth AP1/3L) site located in the U5
region. Van Lint and colleagues have demonstrated this region
to be a binding site for NF-AT which is involved to a low
degree in transcriptional activation of the HIV-1 LTR (52).
We did not see a signiﬁcant change in the level of expression
when the AP1/3L mutation was added to sinLTR(DS) to
create sinLTR(ADS) (Fig. 8A). We further added the
(CT)
3 mutation to this construct to produce sinLTR
(ADCS) and found that this mutation did not alter the ex-
pression of eGFP (Fig. 8A), conﬁrming our ﬁnding in the
promoter assay that the CT triplet does not play a role in
transcriptional activation.
We also used this system to evaluate the possibility that the
previously identiﬁed HIV-1 Inr ascribed to the sequence 6t o
30 relative to the beginning of R at 1 (56) may play a role
in promoting transcription from the sinLTR. To alter the se-
quence at the beginning of this Inr, we deleted an additional 31
bp of U3, including the sequence 6t o1 (see Materials and
Methods). Iwakuma et al. demonstrated that the U3 region can
tolerate deletion of all but the 5 24 bp which constitute the left
attachment (attL) site, which is recognized by integrase (23).
This construct, designated sinLTR(attL) (Fig. 1C), expressed
at nearly the same level as the standard sinLTR vector. Since
other investigators have provided evidence that the sequence
5 of the ﬁrst base of R may not be important for Inr function
in HIV-1 (41), we also constructed a vector in which the GGG
sequence at the U3-R junction was mutated to TTT, which was
shown to severely decrease transcription from the HIV-1 LTR,
presumably by altering function of the Inr (41). This vector,
designated sinLTR(T
3), also expressed at nearly the same level
as the standard sinLTR (Fig. 8A). Finally we constructed a
vector combining the attL with the T
3 mutation which demon-
strated only a mild defect in expression (Fig. 8A), indicating
that the start site Inr does not play a signiﬁcant role in the
residual promoter activity from the sinLTR.
Mutation of the LR SP1 site decreases vector titer. Having
demonstrated that mutation of the DBF1 and SP1 sites in the
LR can signiﬁcantly decrease transcription from the sinLTR,
we next analyzed whether this mutation alters the titers of
mutated vectors. We thus constructed versions of the sinLTR-
hCMV-eGFP vector containing mutations of individual or
multiple sites and then packaged them with HIV Gag/Pol and
VSV-G and determined their titers in duplicate on 293 cells
(see Materials and Methods). A vector containing the DBF1
and SP1 mutations had a titer which was only 20.7% of the titer
of the nonmutated vector (Fig. 8B). Analysis of vectors with
the DBF1 and SP1 sites mutated individually permit us to
attribute the decrease in titer solely to the SP1 mutation (Fig.
8B).
DISCUSSION
When creation of SIN lentiviral vectors was ﬁrst reported
(33, 60), the lack of transcripts from the LTR as assayed by
Northern blot was provided as evidence of the complete abo-
lition of LTR-mediated transcripts in these vectors. We have
also observed that the level of transcription from the sinLTR is
generally insufﬁcient to be detectable by Northern analysis
(data not shown). We were, however, concerned that this issue
had not been investigated thoroughly enough, and that
prompted us to develop more sensitive methods for detecting
transcripts derived from the LTR of SIN vectors.
In this work, we have presented four independent lines of
evidence that the sinLTR lentivectors retain promoter activity
near the 5 LTR which is responsible for the production of
full-length vector genome transcripts competent for encapsi-
dation and integration. First, we demonstrated that transduc-
tion of a lentiviral packaging cell line with a standard SIN
lentivector results in the production of viable vector particles
8432 LOGAN ET AL. J. VIROL.containing full-length SIN lentivector genomes (Fig. 2). We
also demonstrated that an HSV-TK gene placed downstream
of the sinLTR, but upstream of the vector’s internal promoter,
is produced in quantities high enough to render cells contain-
ing this vector partially susceptible to GCV-induced cell death
(Fig. 3). Additionally, we demonstrated that SIN lentivectors
containing no internal promoter express an eGFP transgene
located directly downstream of the packaging signal and Rev-
responsive element located at the 5 end of the vector (Fig. 4).
Finally, using RT-PCR, we demonstrated that transcripts ini-
tiated at the U3-R junction of the 5 LTR in SIN lentivectors
can be readily detected (Fig. 5), and using this assay, we con-
clude that the sinLTR/LR retains approximately 15% of the
transcriptional activity of the wtLTR, depending on cell type.
After demonstrating the residual promoter activity in
sinLTR vectors, we then sought to identify the elements re-
maining in the standard sinLTR vector constructs which are
responsible for this activity. To provide some insight as to
whether transcription initiation on the sinLTR was similar to
that seen on the wtLTR, we rigorously analyzed the respon-
siveness of the sinLTR to the HIV-1 transactivator Tat. Tat
transactivates the transcription of HIV-1 by binding to the
TAR loop in nascent transcripts and directing the phosphory-
lation of the C-terminal domain of RNAP II by CDK9 which
FIG. 8. Evaluation of LTR and LR mutations in sinLTR vectors. (A) The promoterless vectors wtLTR-eGFP and sinLTR-eGFP and mutant
forms of sinLTR-eGFP bearing the mutations indicated on the left were used to transduce Jurkat cells in triplicate with equivalent p24
concentrations of each vector. One week after transduction, the cells were analyzed for expression of eGFP. At the same time, genomic DNA from
each pool was assayed by PCR to determine the transduction efﬁciency from each vector. The graph depicts the expression from each vector after
correction for the differing transduction efﬁciencies from each vector, all normalized to the expression from the sinLTR-eGFP vector lacking
additional mutations. (B) Mutants of the sinLTR-hCMV-eGFP vector (designated sinLTR here) were generated to have the DBF1 and SP1
mutations either alone or in combination. These vectors were packaged and their titers were determined on 293 cells (see Materials and Methods).
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cells transduced with wtLTR-eGFP and sinLTR-eGFP vectors,
we observed high-level and dose-dependent transactivation of
the wtLTR by Tat (Fig. 6). In contrast, the level of transcrip-
tion from the sinLTR was unchanged, even at the highest level
of transfected Tat plasmid (Fig. 6). We thus conclude that the
RNAP II holoenzyme that nucleates on the sinLTR is not Tat
responsive.
The lack of Tat-responsiveness provides a clue that the pro-
cess of transcriptional initiation on the sinLTR involves tran-
scriptional activators which nucleate a RNAP II holoenzyme
capable of only basal levels of transcription. Thus, we analyzed
the potential for other elements in the LTR and LR to be
involved in this basal promoter activity. An obvious candidate
for involvement in promoting transcription from the sinLTR is
the HIV-1 start site Inr, which has been identiﬁed to encom-
pass the sequence 6t o30 relative to the beginning of R at
1 (56). Inr elements are found near the transcriptional start
sites of many TATA-containing and TATA-less promoters
(reference 47 and references therein). In the latter, the Inr is
usually thought to serve as a nucleation point for the RNAP II
holoenzyme and thus dictates the site at which transcripts
begin. It is notable that HIV-1 has an Inr at the traditional
transcriptional initiation site which has been shown to be in-
volved in initiating transcription from the LTR in vivo (56).
There is evidence, however, that the HIV-1 start site Inr does
not function efﬁciently in the absence of a TATA sequence at
the normal 30 position relative to the transcriptional start
site (56). Indeed, a very high level of conservation of the core
promoter TATA sequence has been noted in proviral isolates
from HIV-1-infected individuals, indicating its importance to
HIV-1 viability (12). With the standard 400-bp U3 deletion
used to create the sinLTR, the TATA sequence at this location
is entirely removed (Fig. 1B). The remaining U3 sequence in
the sinLTR does not fortuitously contain a TATA sequence,
nor does it contain a sequence which can be predicted to
function as a noncanonical TATA sequence as determined by
analysis with Matinspector (39) (Genomatix).
We have now presented substantial evidence that the HIV-1
Inr is not responsible for the residual promoter activity in the
sinLTR. In our promoter screen, the sinLTR U3-R-U5 seg-
ment alone had no detectable promoter activity (Fig. 7A).
Additionally, lentivector constructs containing a deletion that
removes the ﬁrst six nucleotides of the HIV-1 Inr, a mutation
that converts the ﬁrst three nucleotides of R from GGG to
TTT, and a mutant combining both of those modiﬁcations,
were capable of expressing transgene at levels near that of the
control sinLTR vector containing no mutations (Fig. 8A).
From this, we conclude that transcription from the LTR in SIN
vectors does not require the HIV-1 Inr sequence at the U3-R
junction to be intact.
Several studies have demonstrated that factors that bind
downstream of the transcription initiation site play a key role
in transcriptional activation from the LTR in integrated HIV-1
proviruses. This led us to question whether the LR binding
sites may be involved in basal transcription from the sinLTR.
We approached this issue by ﬁrst demonstrating that the LR
from the sinLTR vector is indeed capable of promoting tran-
scription (Fig. 7A) and that it does so in a manner which
initiates transcription at or upstream of the ﬁrst nucleotide of
R (Fig. 7B). After mutating the binding sites for DBF1 and
SP1, we observed a signiﬁcant decrease in the transcriptional
activity from the LR, both as an isolated fragment in a pro-
moter screen (Fig. 7A) and as a mutation to the LR of a
sinLTR vector (Fig. 8A). The mutations we made were previ-
ously demonstrated by Van Lint et al. to signiﬁcantly eliminate
binding of the factors to the mutated sites (52). Although we
could not eliminate all sources of transcriptional activation
from the LR, we have demonstrated that mutation of DBF1
and SP1 sites in this region can reduce residual transcription
from the sinLTR to roughly 20% of its original level. Unfor-
tunately, mutation of the SP1 site is also accompanied by a
signiﬁcant (roughly 80%) drop in titer (Fig. 8B). The SP1 site
in the LR overlaps stem-loop 1 (SL1) of the  region (Fig. 9).
Although the SP1 site mutation we have used from Van Lint et
al. (52) was selected to avoid disruption of SL1, it is possible
that other thermodynamically favorable conformations of 
are disrupted by the mutation, leading to a decrease in tran-
script packaging and thus vector titer. Indeed, it has been
demonstrated that maintenance of the SL1 stem-loop is crucial
to the packaging of HIV-1 (5, 6, 19, 21, 55). Maintaining a high
vector titer is of pivotal importance for the transduction of
certain cell types, such as hematopoietic stem cells (20, 43, 50),
so the decrease in titer we have seen with the sinLTR vector
bearing the SP1 mutation will limit its utility. It remains to be
determined whether other mutations to the SP1 site will be
superior in terms of both eliminating factor binding and main-
taining packageability and infectivity of the vector genomes.
In conclusion, our ﬁnding that HIV-1-derived vectors con-
taining the SIN deletion in the U3 region of the LTR are
capable of expressing full-length genomic transcripts raises the
possibility that sinLTR vectors may be susceptible to mobili-
zation by wild-type HIV-1, which will be a concern when these
vectors enter into clinical usage. Due to the susceptibility of
only certain cell types to HIV-1 infection, many potential users
of HIV-1-derived vectors need never worry about mobilization
(e.g., those using lentivectors to transduce nonhematopoietic
tissues). Mobilization is, however, a possibility in the case of
lentivector-transduced progenitor or mature hematopoietic
FIG. 9. Predicted structure of  stem-loops. The Mfold prediction
of the most thermodynamically stable conformation of  stem-loops 1
to 3 is diagrammed. The four nucleotides mutated in the SP1 site are
indicated.
8434 LOGAN ET AL. J. VIROL.cells susceptible to HIV-1 infection, and this should be borne
in mind until a sinLTR vector with a fully transcriptionally
silent LTR can be developed. The lack of Tat-responsiveness
of the sinLTR is fortuitous, since even in their present conﬁg-
uration, sinLTR vectors will be at an extreme disadvantage for
mobilization by HIV-1. If a cell transduced with a sinLTR
vector were to become infected with HIV-1, the virus will
transcribe its own genome at very high levels in the presence of
Tat, whereas the sinLTR vector would only be capable of
expression at a basal level. This will result in HIV-1 genomic
transcripts far outnumbering vector genomic transcripts, mak-
ing the vector transcripts unlikely to be packaged.
Another issue to be considered on the basis of our data is
that the basal transcription from the sinLTR may have some
signiﬁcance for other lentivector applications such as the de-
velopment of transgenic animals by using lentiviral vectors
carrying expression cassettes with cell type-speciﬁc internal
promoters (30). It is possible that low-level expression from the
sinLTR may be adequate for the production of some transgene
in a non-cell-type-speciﬁc manner. Such studies may beneﬁt
from a decrease in the basal transcription from the sinLTR
achieved by mutating the LR DBF1 and SP1 sites.
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